Bausch + Lomb Expands OTC Product Line with Acquisition of Blink® Eye Drops
July 06 2023 - 7:00AM
Business Wire
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye
health company dedicated to helping people see better to live
better, today announced an affiliate has purchased the Blink®
product line of eye and contact lens drops from Johnson &
Johnson Vision.* The strategic acquisition is the latest example of
the company’s commitment to increasing over-the-counter (OTC)
consumer convenience in eye care.
“There’s a growing need for relieving the symptoms of dry eyes
and dry contact lenses, and OTC products are often the first option
consumers choose,” said John Ferris, executive vice president,
Consumer, Bausch + Lomb. “The addition of Blink expands our robust
portfolio of OTC eye care brands, enabling us to provide more
choices for consumers and eye care professionals.”
According to a 2022 Gallup Study, 57% of American adults report
suffering from eye dryness, and of them, nearly half (48%) use OTC
lubricant drops to obtain relief. The incidence is increasing, with
a strong correlation between the amount of time spent on digital
devices and reported dry eyes.1 In addition, contact lens
discomfort and contact lens dryness impacts a third of the 45
million contact lens wearers in the United States.2,3,4
About Blink® Eye Drops
The Blink portfolio of eye drops consists of a variety of eye
drops and contact lens rewetting drops that provide immediate and
long-lasting symptom relief. The products that are part of the
acquisition include the following:
- Blink® Tears Lubricating Eye Drops;
- Blink® Tears Preservative Free Lubricating Eye Drops;
- Blink GelTears® Lubricating Eye Drops;
- Blink® Triple Care Lubricating Eye Drops;
- Blink Contacts® Lubricating Eye Drops; and
- Blink-N-Clean® Lens Drops.
More information about Blink eye drops can be found at
www.justblink.com.
Under the terms of the deal, Bausch + Lomb agreed to acquire the
Blink product line for $106.5 million with cash on hand.
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift
of sight for millions of people around the world – from the moment
of birth through every phase of life. Its comprehensive portfolio
of more than 400 products includes contact lenses, lens care
products, eye care products, ophthalmic pharmaceuticals,
over-the-counter products and ophthalmic surgical devices and
instruments. Founded in 1853, Bausch + Lomb has a significant
global research and development, manufacturing and commercial
footprint with approximately 13,000 employees and a presence in
nearly 100 countries. Bausch + Lomb is headquartered in Vaughan,
Ontario with corporate offices in Bridgewater, New Jersey. For more
information, visit www.bausch.com and connect with us on Twitter,
LinkedIn, Facebook and Instagram.
Forward-looking Statements
This news release may contain forward-looking statements, which
may generally be identified by the use of the words “anticipates,”
“hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,”
“will,” “may,” “believes,” “estimates,” “potential,” “target,” or
“continue” and variations or similar expressions. These statements
are based upon the current expectations and beliefs of management
and are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include,
but are not limited to, the risks and uncertainties discussed in
Bausch + Lomb’s filings with the U.S. Securities and Exchange
Commission and the Canadian Securities Administrators, which
factors are incorporated herein by reference. Readers are cautioned
not to place undue reliance on any of these forward-looking
statements. These forward-looking statements speak only as of the
date hereof. Bausch + Lomb undertakes no obligation to update any
of these forward-looking statements to reflect events or
circumstances after the date of this news release or to reflect
actual outcomes, unless required by law.
References
- MultiSponsor Surveys, Inc. The 2022 Study of Dry Eye Sufferers.
August 2022.
- MultiSponsor Surveys, Inc. The 2021 Study of the U.S. Consumer
Contact Lens Market. December 2021.
- American Optometric Association. www.aoa.org.
- Centers for Disease Control and Prevention. www.cdc.gov.
*Johnson & Johnson Vision represents the products and
services of Johnson & Johnson Surgical Vision, Inc., Johnson
& Johnson Vision Care, Inc. and the affiliates of both.
© 2023 Bausch + Lomb.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230706964776/en/
Investors: George Gadkowski
george.gadkowski@bausch.com
Allison Ryan allison.ryan@bausch.com (877) 354-3705 (toll free)
(908) 927-0735
Media: T.J. Crawford tj.crawford@bausch.com (908)
705-2851
Lainie Keller lainie.keller@bausch.com (908) 927-1198
Bausch plus Lomb (NYSE:BLCO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bausch plus Lomb (NYSE:BLCO)
Historical Stock Chart
From Jul 2023 to Jul 2024